Skip to main content
JIANGSU SIHUAN BIOENGINEERING CO.,LTD logo

JIANGSU SIHUAN BIOENGINEERING CO.,LTD — Investor Relations & Filings

Ticker · 000518 ISIN · CNE0000001P8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,779 across all filing types
Latest filing 2026-04-17 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 000518

About JIANGSU SIHUAN BIOENGINEERING CO.,LTD

https://www.000518shsw.com

Jiangsu Sihuan Bioengineering Co., Ltd. specializes in the research, development, and production of biopharmaceutical products and traditional Chinese medicines. The company’s core product line features genetic engineering drugs, including recombinant human interleukin-2 (rhIL-2) and recombinant human granulocyte colony-stimulating factor (rhG-CSF). Its manufacturing capabilities encompass various dosage forms such as injections, capsules, and tablets, adhering to rigorous quality standards. In addition to its pharmaceutical core, the company manages ecological restoration and landscape engineering initiatives. The organization focuses on leveraging biotechnology to provide therapeutic solutions for oncology and immune-related conditions, maintaining a commitment to scientific innovation and clinical efficacy.

Recent filings

Filing Released Lang Actions
江苏四环生物股份有限公司内控审计报告
Regulatory Filings
2026-04-17 Chinese
江苏四环生物股份有限公司非经营性资金占用及其他关联资金往来情况汇总表
Regulatory Filings Classification · 90% confidence The document is a tabular summary of non-operating fund occupation and other related party fund transactions for the year 2025, prepared by a company (江苏四环生物股份有限公司). It contains detailed financial data such as opening balances, amounts incurred, interest, repayments, and closing balances related to non-operating and operating fund transactions with related parties. The document is relatively short (1728 characters) and appears to be a detailed financial disclosure related to related party transactions and fund usage rather than a full annual or interim report. It does not appear to be an announcement or a certification but rather a specific financial disclosure table. Such disclosures typically fall under Regulatory Filings (RNS) as they are compliance-related but do not constitute a full financial report like an Annual Report or Interim Report. Therefore, the best classification is Regulatory Filings (RNS).
2026-04-17 Chinese
江苏四环生物股份有限公司2025年度财务决算报告
Annual Report Classification · 95% confidence The document is titled as a "2025年度财务决算报告" which translates to "2025 Annual Financial Settlement Report". It contains detailed financial data including income, profit, cash flow, assets, liabilities, and segment revenue for the full fiscal year 2025. The report mentions an audit by an accounting firm with an unqualified opinion, indicating it is a finalized audited financial report. The document length is 3954 characters, which is relatively short but contains substantive financial data and analysis, not just an announcement or a certification. It is not a brief announcement or a proxy statement, nor is it a transcript or a presentation. The content aligns with a comprehensive annual financial report rather than a quarterly or interim report. Therefore, the document fits the definition of an Annual Report (10-K) type filing, as it covers the full fiscal year financial performance and audited results. FY 2025
2026-04-17 Chinese
江苏四环生物股份有限公司关于2025年度计提资产减值准备的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Jiangsu Sihuan Bio Co., Ltd. regarding the provision for asset impairment for the fiscal year 2025. It details the accounting policies and methods used for impairment testing and the amounts of impairment provisions made. The document includes specific financial figures related to impairment provisions and their impact on net profit and equity. It also states that the impairment provision has been audited and confirmed by an accounting firm. The document is relatively short (4348 characters) and is focused on a specific accounting event (asset impairment provision) rather than a full financial report. It is not a full annual or interim report, nor is it a simple announcement of a report publication. It is a regulatory announcement about a specific accounting adjustment. Given the detailed financial data and the nature of the content, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2026-04-17 Chinese
江苏四环生物股份有限公司第十届董事会第十八次会议决议公告（1）
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 18th meeting of the 10th Board of Directors of Jiangsu Sihuan Biological Co., Ltd. It includes approvals of the 2025 Annual Report, Board Work Report, Financial Statements, Profit Distribution Plan, remuneration plans for directors and senior management, internal control evaluation report, and other governance matters. The document repeatedly states that these reports and detailed contents are disclosed separately on the official information website (巨潮资讯网) and other media, indicating this document is a meeting resolution announcement rather than the full reports themselves. The document is about board meeting decisions and approvals, which is characteristic of Board/Management Information filings. It is not the full Annual Report (10-K) or Audit Report (AR) because it does not contain the full financial statements or detailed financial data, only references to them. It is not a Regulatory Filing (RNS) because it is a formal board meeting resolution announcement. Therefore, the best fitting category is Board/Management Information (MANG). The document length (3134 characters) and content support this classification with high confidence.
2026-04-17 Chinese
2025年年度审计报告
Regulatory Filings
2026-04-17 Chinese

Browse filings by year

29 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.